Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORT-LGV: 7-day doxycycline for asymptomatic anal lymphogranuloma venereum
2025-524978-42-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxycycline in lymphogranuloma venereum (LGV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Planned start Oct 2026; status: authorised.
02
Drugs
doxycycline
03
Conditions
lymphogranuloma venereum (LGV)
Beyond the preview
Go deeper on 2025-524978-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524978-42-00.